Literature DB >> 20204473

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Philippe Jacqmin1, Lynn McFadyen, Janet R Wade.   

Abstract

Disease progression modelling can provide information about the time course and outcome of pharmacological intervention on the disease. The basic PK/PD principles of proliferative and circular systems within the context of modelling disease progression and the effect of treatment thereupon are illustrated with the goal to better understand/predict eventual clinical outcome. Circular/proliferative systems can be very complex. To facilitate the understanding of how a dosing regimen can be defined in such systems we have shown the derivation of a system parameter named the Reproduction Minimum Inhibitory Concentration (RMIC) which represents the critical concentration at which the system switches from growth to extinction. The RMIC depends on two parameters (RMIC = (R(0) - 1) x IC(50)): the basic reproductive ratio (R(0)) a fundamental parameter of the circular/proliferative system that represents the number of offspring produced by one replicating species during its lifespan, and the IC(50), the potency of the drug to inhibit the proliferation of the system. The RMIC is constant for a given system and a given drug and represents the lowest concentration that needs to be achieved for eradication of the system. When exposure is higher than the RMIC, success can be expected in the long term. Time varying inhibition of replicating species proliferation is a natural consequence of the time varying inhibitor drug concentrations and when combined with the dynamics of the circular/proliferative system makes it difficult to predict the eventual outcome. Time varying inhibition of proliferative/circular systems can be handled by calculating the equivalent effective constant concentration (ECC), the constant plasma concentration that would give rise to the average inhibition at steady state. When ECC is higher than the RMIC, eradication of the system can be expected. In addition, it is shown that scenarios that have the same steady state ECC whatever the dose, dosage schedule or PK parameters have also the same average R (0) in the presence of the inhibitor (i.e. R (0-INH)) and therefore lead to the same outcome. This allows predicting equivalent active doses and dosing schedules in circular and proliferative systems when the IC(50) and pharmacokinetic characteristics of the drugs are known. The results from the simulations performed demonstrate that, for a given system (defined by its RMIC), treatment success depends mainly on the pharmacokinetic characteristics of the drug and the dosing schedule.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20204473      PMCID: PMC2861178          DOI: 10.1007/s10928-010-9151-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  32 in total

1.  Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development.

Authors:  A N Phillips; M Youle; M Johnson; C Loveday
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

2.  Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells.

Authors:  G A Funk; M Fischer; B Joos; M Opravil; H F Günthard; B Ledergerber; S Bonhoeffer
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

Review 3.  Models of viral kinetics and drug resistance in HIV-1 infection.

Authors:  S Bonhoeffer
Journal:  AIDS Patient Care STDS       Date:  1998-10       Impact factor: 5.078

Review 4.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

5.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

Review 6.  Model-based drug development.

Authors:  R L Lalonde; K G Kowalski; M M Hutmacher; W Ewy; D J Nichols; P A Milligan; B W Corrigan; P A Lockwood; S A Marshall; L J Benincosa; T G Tensfeldt; K Parivar; M Amantea; P Glue; H Koide; R Miller
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

7.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.

Authors:  M A Nowak; S Bonhoeffer; G M Shaw; R M May
Journal:  J Theor Biol       Date:  1997-01-21       Impact factor: 2.691

Review 8.  What do we really know about antibiotic pharmacodynamics?

Authors:  B W Gunderson; G H Ross; K H Ibrahim; J C Rotschafer
Journal:  Pharmacotherapy       Date:  2001-11       Impact factor: 4.705

9.  Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system.

Authors:  Yangxin Huang; Dacheng Liu; Hulin Wu
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

10.  A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients.

Authors:  Line Labbé; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-20       Impact factor: 2.745

View more
  10 in total

1.  From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: application to drug development.

Authors:  Jing Fang; Pravin R Jadhav
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-08       Impact factor: 2.745

Review 2.  Clinical pharmacology = disease progression + drug action.

Authors:  Nick Holford
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

3.  Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations.

Authors:  Chihiro Hasegawa; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-05-26       Impact factor: 2.745

4.  From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.

Authors:  Jing Fang; Pravin R Jadhav
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-27       Impact factor: 2.745

5.  Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.

Authors:  Klaus Romero; Vikram Sinha; Sandra Allerheiligen; Meindert Danhof; Jose Pinheiro; Naomi Kruhlak; Yaning Wang; Sue-Jane Wang; John-Michael Sauer; J F Marier; Brian Corrigan; James Rogers; H J Lambers Heerspink; Tawanda Gumbo; Peter Vis; Paul Watkins; Tina Morrison; William Gillespie; Mark Forrest Gordon; Diane Stephenson; Debra Hanna; Marc Pfister; Richard Lalonde; Thomas Colatsky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-07       Impact factor: 2.745

6.  The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.

Authors:  Phylinda L S Chan; Philippe Jacqmin; Marc Lavielle; Lynn McFadyen; Barry Weatherley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-19       Impact factor: 2.745

7.  On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Authors:  Nahor Haddish-Berhane; Dhaval K Shah; Dangshe Ma; Mauricio Leal; Hans-Peter Gerber; Puja Sapra; Hugh A Barton; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-10       Impact factor: 2.745

8.  A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design.

Authors:  Vincent H Tam; Michael Nikolaou
Journal:  PLoS Comput Biol       Date:  2011-01-06       Impact factor: 4.475

9.  Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.

Authors:  P Jacqmin; J R Wade; B Weatherley; E Snoeck; S Marshall; L McFadyen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-08-14

10.  Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms.

Authors:  Salvatore D'Agate; Timothy Wilson; Burkay Adalig; Michael Manyak; Juan Manuel Palacios-Moreno; Chandrashekhar Chavan; Matthias Oelke; Claus Roehrborn; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2020-04-14       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.